This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 23 for:    influenza and universal
Previous Study | Return to List | Next Study

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified September 2017 by GlaxoSmithKline
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT03275389
First received: August 29, 2017
Last updated: September 7, 2017
Last verified: September 2017
  Purpose
The purpose of this study is to assess the reactogenicity, safety and immunogenicity of different formulations of GlaxoSmithKline (GSK) Biologicals' investigational supra-seasonal universal influenza vaccines (SUIVs) (unadjuvanted or adjuvanted) in 18 to 39 year-old healthy subjects. Subjects will be enrolled and vaccinated with one or 2 primary dose(s) followed by a booster dose one year later.

Condition Intervention Phase
Influenza, Human Biological: D-SUIV Formulation 1 Biological: D-SUIV Formulation 2 Biological: D-SUIV Formulation 3 Biological: D-SUIV Formulation 4 Biological: D-SUIV Formulation 5 Biological: D-SUIV Formulation 6 Biological: D-SUIV Formulation 7 Biological: D-SUIV Formulation 8 Biological: D-SUIV Formulation 9 Biological: Placebo Biological: FLU-D-QIV Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:

The site staff will work in an observer-blind manner during the entire study. As the vaccines appearance and preparation are different, two teams of study personnel will be set up:

  • A team of unblinded personnel (responsible for the reception, preparation and administration of the vaccines).
  • A team of blinded personnel (responsible for the clinical safety evaluation of the subjects).
Primary Purpose: Prevention
Official Title: Reactogenicity, Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Occurrence of solicited local and general adverse events (AEs) [ Time Frame: During the 7-day follow-up period (i.e. on the day of vaccination and 6 subsequent days) after each vaccine dose ]

    Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product to be recorded as endpoints in the clinical study.

    The presence/occurrence/intensity of well defined AEs is actively solicited from the study participant during a specified post-vaccination follow-up period.


  • Occurrence of unsolicited AEs [ Time Frame: During the 28-day follow-up period (i.e. on the day of vaccination and 27 subsequent days) after each vaccine dose. ]
    Any untoward medical occurrence in a patient or clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms.

  • Occurrence of hematological and biochemical laboratory abnormalities after each vaccination [ Time Frame: At each protocol defined visit after Day 1 until Visit 12 (i.e. at Days 8, 29, 57, 64 and 85 and Month 8, Month 14, Month 14 + 7 days, Month 14 +28 days, Month 20 and Month 26). ]
    Any hematological or biochemical laboratory abnormality at each visit subsequent to Day 1

  • Occurrence of Medically Attended Events (MAEs) [ Time Frame: Throughout the entire study period (Day 1 to Month 26) ]
    MAEs are adverse events with medically-attended visits that are not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason.

  • Occurrence of Potential Immune-Mediated Diseases (pIMDs) [ Time Frame: Throughout the entire study period (Day 1 to Month 26) ]
    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

  • Occurrence of Serious Adverse Events (SAEs) [ Time Frame: Throughout the entire study period (Day 1 to Month 26) ]
    A SAE is any untoward medical occurrence that: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

  • Evaluation of levels of anti-H1 stalk antibody titers by ELISA [ Time Frame: At pre-vaccination (Day 1) and at 28 days post Dose 1 and Dose 2 (i.e. at Day 29 and Day 85). ]

    The following aggregate variables will be calculated for the above parameters with 95% CI

    • Seropositivity rates and geometric mean titers (GMTs).

  • Evaluation of levels of anti-H1 stalk antibody titers by MN assay [ Time Frame: At pre-vaccination (Day 1) and at 28 days post Dose 1 and Dose 2 (i.e. at Day 29 and Day 85). ]

    The following aggregate variables will be calculated for the above parameters with 95% CI

    • Seropositivity rates and geometric mean titers (GMTs).

  • Evaluation of levels of anti-H1 stalk antibody titers by ELISA [ Time Frame: From Day 1 to Days 29 and 85. ]

    The following aggregate variables will be calculated for the above parameters with 95% CI:

    • Percentage of subjects with a ≥ 4-fold increase.

  • Evaluation of levels of anti-H1 stalk antibody titers by ELISA [ Time Frame: From Day 1 to Days 29 and 85. ]

    The following aggregate variables will be calculated for the above parameters with 95% CI:

    • Percentage of subjects with a ≥ 10-fold increase.

  • Evaluation of levels of anti-H1 stalk antibody titers by ELISA [ Time Frame: From Day 1 to Days 29 and 85. ]
    Mean geometric increase (MGI) will be calculated for the above parameters with 95% CI

  • Evaluation of levels of anti-H1 stalk antibody titers by MN assay [ Time Frame: From Day 1 to Days 29 and 85. ]

    The following aggregate variables will be calculated for the above parameters with 95% CI:

    • Percentage of subjects with a ≥ 4-fold increase.

  • Evaluation of levels of anti-H1 stalk antibody titers by MN assay [ Time Frame: From Day 1 to Days 29 and 85. ]

    The following aggregate variables will be calculated for the above parameters with 95% CI:

    Percentage of subjects with a ≥ 10-fold increase.


  • Evaluation of levels of anti-H1 stalk antibody titers by MN assay [ Time Frame: From Day 1 to Days 29 and 85. ]
    Mean geometric increase (MGI) will be calculated for the above parameters with 95% CI


Secondary Outcome Measures:
  • Evaluation of adjuvant effect on the anti-stalk immune response in terms of Geometric Mean Titer (GMT) ratio for anti-stalk ELISA titer SUIV+AS03 or AS01/SUIV non-adjuvanted [ Time Frame: At 28 days post vaccination (i.e. at Day 29 to evaluate the adjuvant effect post-dose 1 and at Day 85 to evaluate the adjuvant effect post-dose 2). ]
    GMT ratio for anti-stalk ELISA titer SUIV+AS03 or AS01/SUIV non-adjuvanted

  • Evaluation of levels of anti-H1 stalk antibody titers by ELISA post-each vaccination [ Time Frame: At the protocol defined blood sampling timepoints for antibody determination (i.e. at Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26). ]
    Seropositivity rates and GMTs will be calculated for the mentioned parameters with 95% CI

  • Evaluation of levels of anti-H1 stalk antibody titers by ELISA post-each vaccination [ Time Frame: From Day 1 to Day 29, Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    - Percentage of subjects with a ≥ 4-fold increase in antibody titers.


  • Evaluation of levels of anti-H1 stalk antibody titers by ELISA post-each vaccination [ Time Frame: From Day 1 to Day 29, Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    • Percentage of subjects with a ≥ 10-fold increase in antibody titers.

  • Evaluation of levels of anti-H1 stalk antibody titers by ELISA post-each vaccination [ Time Frame: From Day 1 to Day 29, Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]
    Mean Geometric Increase (MGI) will be calculated for the mentioned parameters with 95% CI.

  • Evaluation of levels of anti-H1 stalk antibody titers by MN assays post-each vaccination. [ Time Frame: At Days 1, 29, 85, Month 14, Month 14 + 28 days and Month 26. ]
    Seropositivity rates and GMTs will be calculated for the mentioned parameters with 95% CI

  • Evaluation of levels of anti-H1 stalk antibody titers by MN assay post-each vaccination. [ Time Frame: From Day 1 to Day 29, Day 85, Month 14, Month 14 + 28 days and Month 26 ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    - Percentage of subjects with a ≥ 4-fold increase in antibody titers by MN assay.


  • Evaluation of levels of anti-H1 stalk antibody titers by MN assay post-each vaccination. [ Time Frame: From Day 1 to Day 29, Day 85, Month 14, Month 14 + 28 days and Month 26 ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    - Percentage of subjects with a ≥ 10-fold increase in antibody titers by MN assay.


  • Evaluation of levels of anti-H1 stalk antibody titers by MN assay post-each vaccination. [ Time Frame: From Day 1 to Day 29, Day 85, Month 14, Month 14 + 28 days and Month 26 ]
    MGI will be calculated for the mentioned parameters with 95% CI

  • Evaluation of levels of anti-H2 and anti-H18 antibody titers by ELISA. [ Time Frame: At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    - Anti-H2 and anti-H18 seropositivity rates and GMTs.


  • Evaluation of levels of anti-H2 and anti-H18 antibody titers by ELISA. [ Time Frame: From Day 1 to Day 29, Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    - Percentage of subjects with a ≥ 4-fold increase in anti-H2 and anti-H18 antibody titers.


  • Evaluation of levels of anti-H2 and anti-H18 antibody titers by ELISA. [ Time Frame: From Day 1 to Day 29, Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    • Percentage of subjects with a ≥ 10-fold increase in anti-H2 and anti-H18 antibody titers.

  • Evaluation of levels of anti-H2 and anti-H18 antibody titers by ELISA. [ Time Frame: From Day 1 to Day 29, Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26. ]
    MGI will be calculated for the mentioned parameters with 95% CI

  • Evaluation of levels of antibody titers by MN assays. [ Time Frame: At Days 1, 29, 85, Month 14, Month 14 + 28 days and Month 26. ]
    Seropositivity rates and GMTs will be calculated for the mentioned parameters with 95% CI for H5N8; H1N1 swine influenza and Quadrivalent inactivated influenza (IIV4) H1N1 vaccine strains.

  • Evaluation of levels of antibody titers by MN assays for H5N8; H1N1 swine influenza and IIV4 H1N1 vaccine strains. [ Time Frame: From Day 1 to Day 29, Day 85, Month 14, Month 14 + 28 days and Month 26. ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    • Percentage of subjects with a ≥ 4-fold increase in antibody titers.

  • Evaluation of levels of antibody titers by MN assays for H5N8; H1N1 swine influenza and IIV4 H1N1 vaccine strains. [ Time Frame: From Day 1 to Day 29, Day 85, Month 14, Month 14 + 28 days and Month 26. ]

    The following aggregate variables will be calculated for the mentioned parameters with 95% CI:

    • Percentage of subjects with a ≥ 10-fold increase in antibody titers.

  • Evaluation of levels of antibody titers by MN assays for H5N8; H1N1 swine influenza and IIV4 H1N1 vaccine strains. [ Time Frame: From Day 1 to Day 29, Day 85, Month 14, Month 14 + 28 days and Month 26. ]
    MGI will be calculated for the mentioned parameters with 95% CI


Estimated Enrollment: 450
Anticipated Study Start Date: September 8, 2017
Estimated Study Completion Date: March 29, 2020
Estimated Primary Completion Date: March 29, 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: D-SUIV Adjuvanted Group 1
Subjects will receive one dose of D-SUIV Formulation 1 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 2 at Month 14
Biological: D-SUIV Formulation 1
1 Primary dose or 1 Booster dose will be administered intramuscularly (IM) in the deltoid region of non-dominant arm.
Biological: D-SUIV Formulation 2
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
Biological: Placebo
1 dose will be administered IM in the deltoid region of non-dominant arm
Experimental: D-SUIV Adjuvanted Group 2
Subjects will receive one dose of D-SUIV Formulation 2 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 1 at Month 14
Biological: D-SUIV Formulation 1
1 Primary dose or 1 Booster dose will be administered intramuscularly (IM) in the deltoid region of non-dominant arm.
Biological: D-SUIV Formulation 2
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
Biological: Placebo
1 dose will be administered IM in the deltoid region of non-dominant arm
Experimental: D-SUIV Adjuvanted Group 3
Subjects will receive one dose of D-SUIV Formulation 1 at Day 1, one dose of D-SUIV Formulation 2 at Day 57 and one booster dose of D-SUIV Formulation 3 at Month 14
Biological: D-SUIV Formulation 1
1 Primary dose or 1 Booster dose will be administered intramuscularly (IM) in the deltoid region of non-dominant arm.
Biological: D-SUIV Formulation 2
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
Biological: D-SUIV Formulation 3
1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
Experimental: D-SUIV Adjuvanted Group 4
Subjects will receive one dose of D-SUIV Formulation 4 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 5 at Month 14
Biological: D-SUIV Formulation 4
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
Biological: D-SUIV Formulation 5
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: Placebo
1 dose will be administered IM in the deltoid region of non-dominant arm
Experimental: D-SUIV Adjuvanted Group 5
Subjects will receive one dose of D-SUIV Formulation 5 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 4 at Month 14
Biological: D-SUIV Formulation 4
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
Biological: D-SUIV Formulation 5
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: Placebo
1 dose will be administered IM in the deltoid region of non-dominant arm
Experimental: D-SUIV Adjuvanted Group 6
Subjects will receive one dose of D-SUIV Formulation 4 at Day 1, one dose D-SUIV Formulation 5 at Day 57 and one booster dose of D-SUIV Formulation 6 at Month 14
Biological: D-SUIV Formulation 4
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
Biological: D-SUIV Formulation 5
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: D-SUIV Formulation 6
1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Experimental: D-SUIV Unadjuvanted Group 1
Subjects will receive one dose of D-SUIV Formulation 7 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 8 at Month 14
Biological: D-SUIV Formulation 7
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: D-SUIV Formulation 8
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: Placebo
1 dose will be administered IM in the deltoid region of non-dominant arm
Experimental: D-SUIV Unadjuvanted Group 2
Subjects will receive one dose of D-SUIV Formulation 8 at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV Formulation 7 at Month 14
Biological: D-SUIV Formulation 7
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: D-SUIV Formulation 8
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: Placebo
1 dose will be administered IM in the deltoid region of non-dominant arm
Experimental: D-SUIV Unadjuvanted Group 3
Subjects will receive one dose of D-SUIV Formulation 7 at Day 1, one dose D-SUIV Formulation 8 at Day 57 and one booster dose of D-SUIV Formulation 9 at Month 14
Biological: D-SUIV Formulation 7
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: D-SUIV Formulation 8
1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Biological: D-SUIV Formulation 9
1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Active Comparator: IIV4 Group
Subjects will receive one dose of Fluarix Quadrivalent at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent at Month 14
Biological: Placebo
1 dose will be administered IM in the deltoid region of non-dominant arm
Biological: FLU-D-QIV
1 Primary dose and 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
Other Name: Fluarix Quadrivalent

Detailed Description:

Current seasonal influenza vaccines show good efficacy when they are well-matched with the circulating virus strains.

However, influenza viruses constantly change their surface glycoproteins that are the targets of most immune responses, allowing them to escape pre-existing immunity, a process called antigenic drift. Therefore, seasonal influenza vaccines have to be reformulated and re-administered on an annual basis. In addition, novel viruses can appear at irregular intervals and cause influenza virus pandemics that can claim millions of lives.

GSK Biologicals is now developing a new influenza vaccine that contains modified inactivated influenza viruses. The purpose of this approach is to elicit an immune response that would protect against all current and future circulating influenza strains without having to administer the vaccine each year.

  Eligibility

Ages Eligible for Study:   18 Years to 39 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the subject prior to performance of any study specific procedure.
  • A male or female between, and including, 18 and 39 years of age at the time of the first vaccination.
  • Healthy subjects without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as established by medical history and clinical examination before first vaccination and laboratory screening tests (the latter being only applicable for subjects enrolled in Phase I).
  • Subjects with no history of influenza vaccination within 6 months prior to first study vaccination and who are willing to forego any influenza vaccination during the entire study period.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • Has practiced adequate contraception for 30 days prior to first vaccination, and
    • Has a negative pregnancy test on the day of vaccination, and
    • Has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series (last vaccination at Month 14).

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines, or planned use during the study period.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose. For corticosteroids, this will mean prednisone ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Administration of long-acting immune-modifying drugs within 6 months before first vaccination, or planned administration any time during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose up to the blood sampling at Day 85 and in the period starting 30 days before booster vaccination at Month 14 up to the blood sample at Month 14 + 28 days.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Previous vaccination against influenza within the 6 months preceding the first vaccination at Visit 1 or planned use of such vaccines during the study period.
  • History of vaccination with a (pre)pandemic influenza vaccine other than an H1N1pdm09 vaccine or history of laboratory-confirmed influenza infection other than seasonal or H1N1pdm09 influenza.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of or current autoimmune disease.
  • Subjects diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in a subject's parent or sibling.
  • History of Guillain-Barré syndrome.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.
  • Hypersensitivity to latex.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 38.0°C / 100.4°F. The preferred location for measuring temperature in this study will be the oral cavity.
    • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
    • For subjects with acute disease and/or fever at the time of enrolment, Visit 1 may be re-scheduled within the allowed time-window.
  • Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period.
  • Blood donation within 30 days before the first study blood sampling or planned blood donation within 30 days before and up to 30 days after any study blood sampling.
  • Pregnant or lactating female.
  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.

Additional criterion applicable for Phase I subjects:

  • Hematological and/or biochemical parameters outside the laboratory normal ranges, unless the laboratory abnormalities are considered not clinically significant by the investigator.
  • Liver enzymes (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) outside of the normal laboratory ranges.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03275389

Contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com

Locations
United States, Kansas
GSK Investigational Site Not yet recruiting
Wichita, Kansas, United States, 67207
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT03275389     History of Changes
Other Study ID Numbers: 207543
2017-001584-20 ( EudraCT Number )
Study First Received: August 29, 2017
Last Updated: September 7, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
URL: http://

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
Safety
Healthy adults
Immunogenicity
Supra-seasonal universal influenza vaccines - inactivated (SUIVs)

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 21, 2017